Vivendi SA (VIV) Given Average Rating of “Buy” by Analysts

Share on StockTwits

Vivendi SA (EPA:VIV) has been given a consensus recommendation of “Buy” by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is €25.43 ($29.57).

VIV has been the topic of several recent analyst reports. UBS Group set a €25.00 ($29.07) target price on shares of Vivendi and gave the stock a “buy” rating in a report on Monday, September 3rd. Morgan Stanley set a €28.00 ($32.56) target price on shares of Vivendi and gave the stock a “buy” rating in a report on Friday, September 7th. Goldman Sachs Group set a €30.00 ($34.88) target price on shares of Vivendi and gave the stock a “buy” rating in a report on Monday, September 10th. Credit Suisse Group set a €24.20 ($28.14) target price on shares of Vivendi and gave the stock a “buy” rating in a report on Tuesday, October 16th. Finally, Cfra set a €23.00 ($26.74) target price on shares of Vivendi and gave the stock a “neutral” rating in a report on Friday, November 16th.

Vivendi has a twelve month low of €16.85 ($19.59) and a twelve month high of €24.87 ($28.92).

About Vivendi

Vivendi SA operates as a content media and communication company in France, rest of Europe, the United States, and internationally. It operates through Universal Music Group, Canal+ Group, Havas, Gameloft, Vivendi Village, and New Initiatives segments. The Universal Music Group segment is involved in the sale of digital and physical recorded music; and exploitation of music publishing rights, as well as provides artist and merchandising services.

Read More: Stock Split

Analyst Recommendations for Vivendi (EPA:VIV)

Receive News & Ratings for Vivendi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivendi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.